Difference between revisions of "Ivermectin has beneficial effects against SARS-COV-2"
| Line 9: | Line 9: | ||
<table class="tables"> | <table class="tables"> | ||
<tr><td>Results</td><td class="h350"><i>Studies</i></td> | |||
<td | <td>Prophylaxis</td> | ||
<td | <td>Early treatment</td> | ||
<td | <td>Late treatment</td> | ||
<td class="h375" | <td class="h375">Patients</td><td class="h450">Authors</td></tr> | ||
<tr><td | <tr><td>All studies</td> | ||
<td class="h350">76</td> | <td class="h350">76</td> | ||
<td><b>83%</b> <span class="rrcls">[74‑89%]</span></td> | <td><b>83%</b> <span class="rrcls">[74‑89%]</span></td> | ||
| Line 24: | Line 24: | ||
</tr><tr><td><span class="desktop | </tr><tr><td><span class="desktop">Peer-reviewed</span><span class="mobile">Peer-reviewed</span></td> | ||
<td class="h350">55</td> | <td class="h350">55</td> | ||
<td><b>83%</b> <span class="rrcls">[73‑90%]</span></td> | <td><b>83%</b> <span class="rrcls">[73‑90%]</span></td> | ||
| Line 33: | Line 33: | ||
</tr><tr><td><span class="desktop | </tr><tr><td><span class="desktop">With GMK/BBC exclusions</span><span class="mobile">MK/BBC exclusions</a></span></td> | ||
<td class="h350">51</td> | <td class="h350">51</td> | ||
<td><b>82%</b> <span class="rrcls">[68‑89%]</span></td> | <td><b>82%</b> <span class="rrcls">[68‑89%]</span></td> | ||
| Line 42: | Line 42: | ||
</tr><tr><td><span class="desktop"> | </tr><tr><td><span class="desktop">>Randomized Controlled Trials</a></span><span class="mobile">>RCTs</a></span></td> | ||
<td class="h350">32</td> | <td class="h350">32</td> | ||
<td><b>84%</b> <span class="rrcls">[25‑96%]</span></td> | <td><b>84%</b> <span class="rrcls">[25‑96%]</span></td> | ||
| Line 51: | Line 51: | ||
</tr><tr><td><span class="desktop"> | </tr><tr><td><span class="desktop">l#fig_fpre">RCTs w/GMK/BBC exclusions</a></span><span class="mobile">l#fig_fpre">RCTs w/GMK/BBC exc.</a></span></td> | ||
<td class="h350">25</td> | <td class="h350">25</td> | ||
<td><b>84%</b> <span class="rrcls">[25‑96%]</span></td> | <td><b>84%</b> <span class="rrcls">[25‑96%]</span></td> | ||
| Line 60: | Line 60: | ||
</tr><tr class="nob"><td class="nob" colspan="7"><i>Percentage improvement with ivermectin treatment</i></td></tr> | </tr><tr class="nob"><td class="nob" colspan="7"><i>Percentage improvement with ivermectin treatment</i></td></tr> | ||
</table> | |||
{{Claim | {{Claim | ||
Revision as of 23:58, 22 January 2022
Ivermectin has beneficial effects against SARS-COV-2 is an argument derived from over 76 independent studies conducted by researchers around the world showing an unambiguous medical benefit in the treatment of patients suffering from SARS-COV-2 infection and the resultant Covid-19 disease.
Reasons & Support 1) Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain significant after exclusions. 49 studies from 45 independent teams in 21 different countries show statistically significant improvements in isolation (37 primary outcome, 34 most serious outcome).
2) Meta analysis using the most serious outcome shows 66% [53‑75%] and 83% [74‑89%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis (excluding all GMK/BBC team studies), for primary outcomes, for peer-reviewed studies, and for RCTs.
3) Results are very robust — in worst case exclusion sensitivity analysis 60 of 76 studies must be excluded to avoid finding statistically significant efficacy.
| Results | Studies | Prophylaxis | Early treatment | Late treatment | Patients | Authors |
| All studies | 76 | 83% [74‑89%] | 66% [53‑75%] | 39% [23‑52%] | 57,647 | 718 |
| Peer-reviewedPeer-reviewed | 55 | 83% [73‑90%] | 68% [50‑80%] | 41% [17‑58%] | 25,228 | 558 |
| With GMK/BBC exclusionsMK/BBC exclusions</a> | 51 | 82% [68‑89%] | 73% [64‑80%] | 53% [29‑69%] | 44,741 | 545 |
| >Randomized Controlled Trials</a>>RCTs</a> | 32 | 84% [25‑96%] | 62% [45‑74%] | 23% [-1‑41%] | 7,032 | 361 |
| l#fig_fpre">RCTs w/GMK/BBC exclusions</a>l#fig_fpre">RCTs w/GMK/BBC exc.</a> | 25 | 84% [25‑96%] | 69% [56‑77%] | 26% [-2‑46%] | 4,423 | 299 |
| Percentage improvement with ivermectin treatment | ||||||
| Statement of the claim | Ivermectin has beneficial effects against SARS-COV-2 |
| Level of certainty | True |
| Nature | Factual |
| Counterclaim | Ivermectin has no effect or detrimental effects against SARS-COV-2 |
| Dependent on | |
| Dependency of |
|